Analysis Xeris Biopharma Holdings, Inc. (0A8E)
5/28/2024
Analysis of Xeris Biopharma Holdings, Inc. (0A8E)
Xeris Biopharma Holdings, Inc. (0A8E) has shown some interesting price movements recently. The stock closed at 2.68500, with a high of 2.68500 and a low of 2.58200. The Relative Strength Index (RSI) is quite high at 75.17567, indicating the stock may be overbought.Looking at the Moving Average Convergence Divergence (MACD) indicators, the MACD line is above the signal line, with a positive MACD histogram, suggesting a bullish signal.
In terms of moving averages, the Simple Moving Average (SMA), Exponential Moving Average (EMA), and Weighted Moving Average (WMA) are all showing an upward trend, indicating a positive momentum in the stock price.
Overall, based on the RSI, MACD, and moving averages, Xeris Biopharma Holdings, Inc. appears to be in a bullish phase. However, investors should exercise caution due to the high RSI value, which may indicate a potential reversal in the short term.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $83,776,900,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 24.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $92,375,300,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 24.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $386,681,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 37.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $411,555,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 37.
These estimates suggest a moderate growth trend in both quarterly and annual sales for the company, with slightly higher growth expected in the next fiscal year.
Growth estimates
Based on the consensus estimates provided:- The company is expected to experience a growth rate of 7.5% in the current year and 9.7% in the next year.
- For the current quarter, the growth rate is estimated to be 5.6%, while for the next quarter it is projected to be 4.8%.
- Over the next 5 years, the company is expected to have a compound annual growth rate (CAGR) of 11%.
- However, when looking at the past 5 years, the company had a higher CAGR of approximately 20.1%.
Overall, it seems that the company is expected to maintain a solid growth trajectory, with a slightly lower growth rate in the short term compared to the past performance.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $250
- Median: $200
- Average: $202.26
- Current price: $191.57
- Currency: USD
Based on these forecasts, it appears that the analysts are generally optimistic about the future price of the security, with a median estimate of $200. However, there is a wide range of estimates, from a low of $164 to a high of $250. The current price of the security is below both the average and median forecast, suggesting that there may be potential for growth according to analysts.
Earnings
The company's results for the most recent quarter, as of April 30, 2025, have not been provided at this time. The previous results from February 27, 2025, were handled by the Transfer Agent. The results from January 31, 2025, were released after hours. The results from October 31, 2024, were not provided at the time. The results from August 1, 2024, showed an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits for a specific company.In terms of financials, the company has strong cash flow with operating cash flow at $110.56 billion and levered free cash flow at $84.73 billion. The balance sheet shows a total cash of $67.15 billion, total debt of $104.59 billion, and a current ratio of 1.037. The profit margin is 26.31% and the company's fiscal year ends on September 30, 2023. The income statement reveals an EBITDA of $131.39 billion, revenue of $381.62 billion, and a diluted EPS of 6.44.
Moving on to stock statistics, the company has a short ratio of 1.66, with 94.31 million shares shorted out of 15.31 billion float shares. The average 10-day volume is 52.90 million shares, while the average 90-day volume is 62.82 million shares. The stock has a market capitalization of $2.91 trillion.
Valuation metrics show a PEG ratio of 26.21, forward PE of 26.21, and trailing PE of 29.43. The enterprise value is $2.95 trillion, with a price to book ratio of 39.18 and price to sales ratio of 7.62. The stock has an enterprise to EBITDA ratio of 22.75 and enterprise to revenue ratio of 7.73.
The stock price summary includes a beta of 1.26, 50-day moving average of $173.69, and 200-day moving average of $180.79. The stock's 52-week low is $164.08, high is $199.62, and the change over the 52 weeks is 8.25%.
Lastly, in dividends and splits, the company has a payout ratio of 14.93% and a forward annual dividend rate of $1. The ex-dividend date is May 10, 2024, with a dividend date of May 16, 2024. The stock had a 4-for-1 split on August 31, 2020. The 5-year average dividend yield is 0.73% and the trailing annual dividend yield is 0.51%.
Income statement 💸
These are the revenues. Here are the conclusions:1. The company's sales have been increasing steadily over the past four fiscal years.
2. The EBIT (Earnings Before Interest and Taxes) and EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) have also shown a positive trend, indicating improving operational efficiency.
3. The net income has been growing consistently, reflecting the company's profitability.
4. The basic and diluted earnings per share (EPS) have remained relatively stable over the years.
5. The company has managed its operating expenses effectively, as seen in the consistent operating income.
6. The company has been able to maintain a healthy gross profit margin despite fluctuations in the cost of goods sold.
7. The non-operating interest expenses have been relatively stable, indicating effective management of financial costs.
8. Overall, the financial performance of the company seems to be on a positive trajectory based on the revenue data provided.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets fluctuate, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have been increasing steadily, with the highest value in 2019 at $175,697,000,000.
4. Total liabilities have also been increasing, reaching $255,355,000,000 in 2018.
5. Shareholders' equity has been fluctuating, with the highest value in 2018 at $107,147,000,000.
Cash Flow 💶
This is a cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has been relatively stable over the years, indicating consistent operational performance.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show significant variability, with large amounts being spent on common stock repurchase and debt issuance/payments.
6. Investing activities also vary, with significant amounts being spent on the sale and purchase of investments, as well as capital expenditures.
7. Overall, the company's financial activities show a mix of stability in operations and variability in financing and investing decisions.
Earnings estimate
Based on analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average EPS estimate is $1.33, with a range from $1.27 to $1.36. This shows growth compared to the EPS of $1.26 from a year ago.
2. For the next quarter ending on September 30, 2024, the average EPS estimate is $1.53, with a range from $1.44 to $1.63. This also indicates growth compared to the EPS of $1.46 from a year ago.
3. For the current fiscal year ending on September 30, 2024, the average EPS estimate is $6.59, with a range from $6.43 to $6.92. This reflects an increase compared to the EPS of $6.13 from the previous year.
4. Looking ahead to the next fiscal year ending on September 30, 2025, the average EPS estimate is $7.23, with a range from $6.40 to $7.90. This forecast suggests further growth compared to the EPS of $6.59 from the current year.
Overall, the analysts' estimates point towards a positive outlook with expected earnings growth in both the short term and the long term.
MACD of 0A8E
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
